Didier Landais is appointed 4P-Pharma's CEO to lead the company into a new chapter of its development
4P-Pharma, a pioneering biotechnology company based in Lille and specializing in drug regeneration, is thrilled to achieve a significant milestone in its history. During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905514097/en/
DIDIER LANDAIS CEO - 4P-PHARMA
Founded in 2014 by Revital Rattenbach, 4P-Pharma is entering a new era of its development. On September 1st, 2023, Didier Landais succeeds Revital Rattenbach as CEO of 4P-Pharma. She now holds the position of Executive Chairwoman.
With over 30 years of international experience in the pharma/biotech industry, Didier Landais stands out as an executive leader. His career has been marked by accomplishments in key areas such as research and development, strategy, and business development.
His extensive international experience and proven leadership position Didier Landais as the ideal choice for this strategic function. His past achievements attest to his exceptional ability to guide our teams towards excellence, turning ambitious visions into tangible results. Together, the new executive will combine forces to expedite the company's development."
"We stand on the brink of a pivotal period for 4P-Pharma. The appointment of Didier reinforces our commitment to innovation and growth. His passion for scientific research, coupled with his profound market understanding, will propel forward our mission to transform how we approach health and well-being, driving dynamics of success." stated Revital Rattenbach, 4P-Pharma’s Executive Chairwoman
A strong expertise both in France and internationally, to accelerate the development of 4P-Pharma.
Didier Landais holds a Ph.D. in Molecular and Cellular Biology from the University Louis Pasteur (Strasbourg), as well as an Executive MBA from ESSEC (Paris). He started his career as a researcher and oncology project leader at the Gene Therapy Division of RPR-Gencell (Sanofi) before assuming the role of Director of Business Development and General Manager of Cell Therapy, overseeing the international development of a cancer vaccine at IDM Pharma. He has also held positions including Director of Development at Biotecnol and Chief Business Officer at Genome Profiling. Under his leadership as Global Head of Licensing, Servier concluded several notable agreements, including with Celsius, Oncodesign, and Seal Rock. More recently, he served as COO and CBO at Labgenius Ltd in London."
"Joining 4P-Pharma is a significant step for me. We are developing high-potential molecules that truly transform patients' lives. With the support of Revital and our dedicated teams, I am confident that we will reach new horizons and push the boundaries of innovation even further." expressed Didier Landais, 4P-Pharma’s CEO.
As CEO, Didier Landais holds the responsibility for the company's overall strategy in terms of science, partnerships, and external growth. Revital Rattenbach, now 4P-Pharma’s Executive Chairwoman, remains actively involved in financial consolidation and strategic directions, ensuring the continuity of the company's founding vision.
4P-Pharma remains deeply committed to its partners, investors, and its mission to provide innovative solutions to global health challenges."
4P-Pharma is a clinical stage biotech company, pioneering in drug regeneration, founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies. The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Najette Chaib – firstname.lastname@example.org 06 18 38 11 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration27.9.2023 18:28:00 EEST | Press release
LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years. The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial. LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months. Sham patients in the previous study will be able to cross over and begin PBM treatment. The LIGHTSITE IIIB extension trial follows the successfully completed LIGHTSITE III trial, which showed a sustained, mean increase in best corrected vision acuity (BCVA) letter score of >5.0 letters from baseline at the 13- and 24-month timepoints (p < 0.0001) using the Co
XPENG Shipped 750 Vehicles to Israel, Coming Closer to G9 and P7's Launch in October27.9.2023 17:02:00 EEST | Press release
XPENG (NYSE: XPEV and HKEX: 9868), a leading smart electric vehicle company, today announced that it has shipped 750 vehicles for the Israeli market, marking this the largest single batch of export this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927239985/en/ Hey XPENG, navigate to Israel! (Photo: Business Wire) The batch left the Guangzhou Port after the conclusion of a ceremony that included local customs officials and port representatives. “We're very grateful for the support of our partners and the local customs officials as we take a significant step toward launching in Israel," said Eric Xu, VP of International Markets, XPENG. "With the help of our local partner, Freesbe, the launch of our smart EVs is just around the corner—and we can't wait." The two models expected to be available in Israel, XPENG P7 and XPENG G9, have also been adapted to meet the preferences of local drivers. Together with Freesbe, wi
SoftServe Debuts Sage, the AI Pathfinder, at Money20/2027.9.2023 16:03:00 EEST | Press release
SoftServe, a premier IT consulting and digital services provider, will debut Sage, the AI Pathfinder, a financial intelligence consultant powered by Generative AI using NVIDIA Avatar Cloud Engine (ACE), at Money20/20 USA. Attendees can interact with the immersive experience offering financial decisioning and education at booth #13117 starting Oct. 22. Sage, the AI Pathfinder, is enhanced with a customized ChatGPT module combined with visual avatars and dynamic content. It features real-time information processing for interactive decision-making to offer personalized financial recommendations. Financial wellness is a struggle for 58% of Americans living paycheck to paycheck. Only 51% have more emergency savings than credit card debt. “A lack of financial literacy is a big part of this problematic equation,” said Filippa Noghani, AVP of Marketing at SoftServe and NYC Fintech Women Board Member. “Generative AI technologies create promising educational opportunities, especially for millenn
PPG’s COLORFUL COMMUNITIES program marks 500th project with makeover at Carnegie Science Center in Pittsburgh27.9.2023 16:00:00 EEST | Press release
PPG (NYSE:PPG) today announced the completion of its 500th COLORFUL COMMUNITIES® project – a colorful and transformational makeover at Carnegie Science Center in Pittsburgh. More than 80 volunteers marked the milestone by creating science-themed murals and applying fresh paint and color in learning spaces around the center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927335327/en/ PPG volunteers completed the 500th COLORFUL COMMUNITIES® project at the Carnegie Science Center in Pittsburgh, kicking off a month-long, worldwide celebration. (Photo: Business Wire) Completion of the 500th Colorful Communities project kicks off a month-long, worldwide celebration of the volunteers, community partners and individuals who have helped to bring color and brightness to PPG communities. From China to the Netherlands, additional projects are planned across the world to mark the milestone. “When we launched the Colorful Communities
Syntropy Announces Collaboration with Evidium to Advance Data-Centric Healthcare27.9.2023 16:00:00 EEST | Press release
Today, Syntropy, a partnership between Merck and Palantir Technologies Inc., announced a collaboration with Evidium, a developer of a healthcare platform that enables AI use in a responsible, reliable, and referenceable manner. The organizations will make end-to-end medical knowledge more computational and improve data quality for clinical research and practice. The coalition will be facilitated through Syntropy’s secure data collaboration platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927301328/en/ Evidium’s Referenced AI platform will play a key role in transforming narrative-form information into AI-ready knowledge at the elemental level. This will allow clinical data to be disseminated and utilized with unprecedented scale and precision. Syntropy’s secure, collaborative ecosystem will enable researchers to review high-quality data, share insights, and apply their findings to clinical trials, helping to gener
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom